Tracking Heart Disease and Stroke in Canada to Promote and Protect the Health of Canadians Through Leadership, Partnership, Innovation and Action in Public Health
Total Page:16
File Type:pdf, Size:1020Kb
Disease Canada in Stroke and Tracking Heart 2009 TrackingTracking HeartHeart DiseaseDisease andand StrokeStroke inin CanadaCanada To promote and protect the health of Canadians through leadership, partnership, innovation and action in public health. — Public Health Agency of Canada Tracking Heart Disease & Stroke in Canada is available on Internet at the following address: www.phac-aspc.gc.ca Également disponible en français sous le titre : Suivi des maladies du cœur et des accidents vasculaires cérébraux au Canada This publication can be made available on request on diskette, large print, audio-cassette and braille. © Her Majesty the Queen in Right of Canada, 2009 Cat.: HP32-3/2009E ISBN: 978-1-100-12541-1 Online: Cat.: HP32-3/2009E-PDF ISBN: 978-1-100-12542-8 Tracking2009 Heart Disease and Stroke in Canada Editorial Board Public Health Agency of Canada Canadian Institute for Health Information Canadian Stroke Network Heart and Stroke Foundation of Canada Statistics Canada Editorial Board Members Dr. Andreas Wielgosz Scientific Editor Public Health Agency of Canada and The Ottawa Hospital Mr. Manuel Arango Heart and Stroke Foundation of Canada Dr. Christina Bancej Public Health Agency of Canada Ms. Asako Bienek Public Health Agency of Canada Dr. Helen Johansen Statistics Canada Dr. Patrice Lindsay Canadian Stroke Network Ms. Wei Luo Public Health Agency of Canada Ms. Angeline Luteyn Canadian Institute for Health Information Mr. Cyril Nair Statistics Canada ex-officio Mr. Philip Quan Public Health Agency of Canada Dr. Paula Stewart Public Health Agency of Canada Mr. Peter Walsh Public Health Agency of Canada Mr. Gregory Webster Canadian Institute for Health Information External Reviewers Dr. Norm Campbell University of Calgary Dr. Jack Tu Institute for Clinical Evaluative Sciences Acknowledgements The Editorial Board would like to acknowledge the following people for their contributions to this report: Dr. O Baclic (Chronic Disease Management Division, PHAC), L Bartlett (The First Nations Information Governance Committee), T Bhatia (Data Coordination and Access Program, PHAC), Dr. M de Groh (Chronic Disease Prevention Division, PHAC), B Foster (Chronic Disease Prevention Division, PHAC), J Francis (Chronic Disease Evidence and Risk Assessment Division, PHAC), M-F Giguere (Strategic Policy Directorate, PHAC), C Gilbert (Chronic Disease Surveillance Division, PHAC), E Jones-McLean (Chronic Disease Prevention Division, PHAC), Dr. J Kahn (Portal Communications), K Lynch, Q Li (Statistics Canada), B Maga (Maga Policy Consultants Ltd.), J MacInnes (Chronic Disease Prevention Division, PHAC), N Martin (Neasa Martin & Associates), Dr. H Morrison (Chronic Disease Science Office, PHAC), B Power (Chronic Disease Management Division, PHAC), R Przybysz (Canadian Institute for Health Information), O Randell (Inuit Tapiriit Kanatami), H Roberge (Strategic Policy Directorate, PHAC), K Roberts (Chronic Disease Surveillance Division, PHAC), P Sales (Douglas Consulting), R Semenciw (Chronic Disease Surveillance Division, PHAC), T Simpson (Chronic Disease Prevention Division, PHAC), J Snider (Tobacco Control Programme, Health Canada), R Susanto (Statistics Canada), S Tanguay (Strategic Policy Directorate, PHAC), E Vanden (Chronic Disease Management Division, PHAC), R Walker (University of Calgary), and F Wang (Chronic Disease Evidence and Risk Assessment Division, PHAC). We acknowledge Dr. RA Hegele and RL Pollex in the writing of Chapter Three – The Genetic Epidemiology of CVD. We acknowledge Dr. MP Lindsay, Dr. M Hill, Dr. MK Kapral, Dr. M Sharma, Dr. S Phillips, and Dr. A Hakim, on behalf of the Canadian Stroke Network (www.canadianstrokenetwork.ca), in the writing of Chapter Five – Stroke. Tracking Heart Disease and Stroke in Canada — Table of Contents of Table Contents List of Figures ...................................................................................................................................................................................................................................................................................... iii List of Tables ........................................................................................................................................................................................................................................................................................ vii Data Highlight / Prevalence of Heart Disease, Stroke, and Risk Factors ................................................................................................................................ 1 Data Highlight / CVD Hospitalizations, 2005/06 .............................................................................................................................................................................................. 2 Data Highlight / CVD Mortality, 2004 ........................................................................................................................................................................................................................ 3 A Few Words from the Chief Public Health Officer ....................................................................................................................................................................................... 4 Executive Summary .......................................................................................................................................................................................................................................................................... 5 Chapter One / CVD in Canada .............................................................................................................................................................................................................................................. 7 Overview ................................................................................................................................................................................................................................................................................................ 7 Many Canadians Have CVD ............................................................................................................................................................................................................................................ 8 CVD Have a Major Impact on Individuals and Families ................................................................................................................................................................... 8 Poor Health .................................................................................................................................................................................................................................................................................. 8 Limitations in Daily Activities .................................................................................................................................................................................................................................. 9 Anxiety and Depression ............................................................................................................................................................................................................................................... 10 CVD Have a Major Economic Impact in Canada ................................................................................................................................................................................. 10 Health Services Help to Manage CVD ............................................................................................................................................................................................................... 13 Team Care ................................................................................................................................................................................................................................................................................... 13 CVD Medication Use ..................................................................................................................................................................................................................................................... 15 Hospitalization ....................................................................................................................................................................................................................................................................... 16 CVD Are a Major Cause of Death ......................................................................................................................................................................................................................... 21 Summary of Highlights ....................................................................................................................................................................................................................................................... 27 Chapter Two / Preventing CVD .........................................................................................................................................................................................................................................